Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study validate BCL-2 as a target across heterogeneous CRPC subtypes
Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou, Wen Jess Li, Han Yu, Amanda Tracz, Justine J. Jacobi, Qiuhui Li, Kent L. Nastiuk, Xin Chen, Jiaoti Huang, Kevin Lin, Mingyu Liu, Changmeng Cai, Yue Lu, , Dean G. Tang
This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.
Signal Transduction and Targeted Therapy · May 1, 2026Peer-reviewedCancer Biology